CITIUS ONCOLOGY, INC.
Financial highlights
| Metric | FY 09/30/25 | FY 09/30/24 | FY 12/31/23 | FY 09/30/23 | FY 12/31/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $6.4M | $4.9M | — | $4.2M | — |
| Operating expenses | $23.5M | $20.6M | — | $12.1M | — |
| Operating income | -$23.5M | -$20.6M | -$1.0M | — | -$138,115 |
| Interest expense | $218,032 | — | — | — | — |
| Pretax income | -$23.7M | -$20.6M | — | -$12.1M | — |
| Income tax expense | $1.1M | $576,000 | — | $576,000 | — |
| Net income | -$24.8M | -$21.1M | $2.4M | -$12.7M | $380,811 |
| Balance Sheet | |||||
| Current assets | $27.5M | $11.0M | $58,200 | $7.7M | $377,344 |
| Total assets | $100.9M | $84.4M | $72.6M | $47.7M | $68.2M |
| Current liabilities | $49.5M | $32.7M | $2.0M | $21.0M | $31,836 |
| Total liabilities | $56.1M | $38.2M | — | $22.2M | — |
| Stockholders' equity | $44.9M | $46.1M | -$2.0M | $25.5M | $345,508 |
| Cash Flow Statement | |||||
| Cash from operations | -$5.5M | $126,353 | -$601,304 | — | -$47,968 |
| Stock-based compensation | $8.3M | $7.5M | — | $2.0M | — |
| Share repurchases | — | — | — | — | $25,000 |
Shares outstanding 93.0M · Free float 19.5%
Annual filing data through FY ended September 30, 2025; float as of July 16, 2026.